Celldex Therapeutics Inc. (CLDX) said Tuesday that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).
from RTT - Biotech https://ift.tt/3lLyW63
via IFTTT
No comments:
Post a Comment